Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 434 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Retinal Vascular Disorders Clear all

Conditions: Irvine-Gass Syndrome
Interventions: Aflibercept; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Macular Edema, Central Retinal Vein Occlusion
Interventions: Ozurdex, Ranibizumab, Combination Ozurdex with Ranibizumab PRN; Drug
Lead sponsor: Valley Retina Institute; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 5
States / cities: Beverly Hills, California • Lakeland, Florida • Winter Haven, Florida + 2 more

Conditions: Anemia of Prematurity
Interventions: Red blood cell transfusion; Procedure
Lead sponsor: McMaster University; Other
Eligibility: Up to 48 Hours
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Albany, New York • Brooklyn, New York

Conditions: Diabetic Macular Edema, Diabetic Retinopathy
Interventions: AVD-104; Drug
Lead sponsor: Aviceda Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Erie, Pennsylvania • Dallas, Texas • Wichita Falls, Texas

Conditions: Diabetic Retinopathy
Interventions: Aminoguanidine; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Macular Edema With Central Retinal Vein Occlusions
Interventions: Aflibercept (2.0 mg); Drug
Lead sponsor: Northern California Retina Vitreous Associates; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Diabetic Retinopathy, Diabetic Macular Edema
Interventions: Ranibizumab (Lucentis), Argon Laser; Drug · Procedure
Lead sponsor: Rocky Mountain Retina Consultants; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Anterior Uveitis (AU), Birdshot Chorioretinitis, Behcet Disease, Herpes Simplex Virus, Juvenile Idiopathic Arthritis (JIA), Spondyloarthritis (SA), Sarcoidosis, Posterior Vitreous Detachment
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 5 Years to 85 Years
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hypertension
Interventions: High Intensity Interval Training (HIIT) Exercise; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 55 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Diabetes
Interventions: Vessel measurements; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 99 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Macular Edema, Retinal Vein Occlusion
Interventions: Fluocinolone Acetonide; Drug
Lead sponsor: Alimera Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 3
States / cities: Lexington, Kentucky • Boston, Massachusetts • Cleveland, Ohio

Conditions: Diabetic Retinopathy, DR
Interventions: Standard of Care, Aflibercept; Drug
Lead sponsor: AbbVie; Industry
Eligibility: Not listed
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 20
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 17 more

Conditions: Diabetic Retinopathy
Interventions: Non-mydriatic color fundus photography with the RetinaVue camera, Referral for dilated eye exam with an eye care professional; Diagnostic Test
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Diabetic Retinopathy, Type 2 Diabetes Mellitus
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 60 Years to 80 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Diabetic Macular Edema
Interventions: IVT Aflibercept, SC CLS-TA; Drug
Lead sponsor: Clearside Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Mountain View, California • The Woodlands, Texas

Conditions: Type 1 Diabetes, Type 2 Diabetes
Interventions: Point of Care Autonomous AI diabetic retinopathy exam; Diagnostic Test
Lead sponsor: Johns Hopkins University; Other
Eligibility: 8 Years to 21 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Branch Retinal Vein Occlusion
Interventions: Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321); Procedure · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more

Conditions: Macular Holes, Epiretinal Membrane, Diabetic Retinopathy, Retinal Detachment, Retinal Disease, Preretinal Fibrosis, Cataract, Ocular Tumor, Strabismus, Healthy
Interventions: Microscope integrated optical coherence tomography; Device
Lead sponsor: Duke University; Other
Eligibility: 4 Weeks and older
Enrollment: 262 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetic Retinopathy
Interventions: Placebo, RG7774; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 33 more

Conditions: Diabetic Retinopathy
Interventions: BI 764524, Sham control of BI 764524; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 13
States / cities: Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more

Conditions: Macular Degeneration
Interventions: Angiography, Laser Treatment; Procedure
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinopathy of Prematurity
Interventions: Handheld Optical Coherence Tomography with OCT Angiography; Device
Lead sponsor: Duke University; Other
Eligibility: Up to 2 Months
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Durham, North Carolina • Philadelphi, Pennsylvania

Conditions: Vitreoretinopathy, Coats' Disease, Exudative Retinopathy, Lattice Degeneration, Retinal Hole, Sickler's Syndrome, Retinal Detachment Rhegmatogenous, Retinal Detachment Exudative, Retinal Detachment Traction
Interventions: Dextenza 0.4Mg Ophthalmic Insert, Pred Forte; Drug
Lead sponsor: Lejla Vajzovic, MD, FASRS; Other
Eligibility: 3 Years to 17 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus, Diabetic Retinopathy, Retinal Degeneration, Retinal Diseases, Eye Diseases, Edema
Interventions: Aflibercept, foselutoclax; Drug
Lead sponsor: Unity Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 19
States / cities: Bakersfield, California • Beverly Hills, California • Huntington Beach, California + 16 more

Search by objective public record fields.

Treatment of Macular Edema After Cataract Surgery with Subconjunctival Aflibercept

Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion

Premature Infants in Need of Transfusion (PINT)

A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema

Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients

NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions

Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema

Quantification & Classification of Inflammatory Cells in Uveitis Using OCT

Improving Age-Related Cognitive Decline With Exercise in Hypertensive Older Adults

Retinal Vessel Measurements as Clinically Useful Predictors in Veterans

Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy

RetinaVue Diabetic Screening

The Relationship Between Advanced Glycation Endproducts and Diabetes

Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema

ACCESS: AI for pediatriC diabetiC Eye examS Study

Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)

Intraoperative OCT Guidance of Intraocular Surgery II

A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic Retinopathy

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

Identification and Treatment of Feeder Vessels in Macular Degeneration

Imaging Retinal Vasculature in Infant Eyes

DEXTENZA in Pediatric Patients Following Retinal Surgery or Laser Treatment Under Anesthesia

Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)